Zenas BioPharma (ZBIO) announce results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease. Obexelimab met the ...
Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...
The UK arm of car giant Nissan lost £888m during its latest financial year ahead of a major recovery plan taking effect, it ...
THE price of a daily pill version of the fat jab Wegovy has gone on sale for the first time today (January 5) has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback